P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial

Ítems similars

• ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL
  per: French, Pim, et al.
  Publicat: (2018)
• P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)
  per: van den Bent, M, et al.
  Publicat: (2018)
• Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
  per: van den Bent, Martin J., et al.
  Publicat: (2015)
• EGFRvIII: the promiscuous mutation
  per: Greenall, Sameer A, et al.
  Publicat: (2016)
• INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
  per: Van Den Bent, Martin, et al.
  Publicat: (2020)